Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab for Relapsing Neuromyelitis Optica: Randomized Double-blind Placebo-controlled Phase 3 Trial
2013-001150-10Phase 3Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Neuromyelitis Optica Spectrum Disorder (NMOSD) comparing Eculizumab with Placebo (2 arms). Primary endpoint: Time to first adjudicated on-trial relapse. Started Jul 2013; status: terminated.
02
Drugs
eculizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on 2013-001150-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001150-10.